EXOC4

Across TCGA pan-cancer cohorts, EXOC4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EXOC4 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXOC4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EXOC4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where EXOC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.923	0.770	.001	64	view →
LUAD	DFS	Median	II,III,IV	0.210	0.801	.002	18	view →
PDAC	DFS	Quartile	III,IV	0.223	0.968	.004	18	view →
CCRCC	OS	Quartile	III,IV	0.832	0.479	.015	11	view →
UCEC	DFS	Median	All	0.955	0.850	.017	10	view →
GBM	OS	Median	All	0.450	0.591	.035	3	view →
LSCC	DFS	Tertile	All	0.524	1.000	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EXOC4–HNSC (OS)

Open the HNSC breakdown →